Double attack on lung cancer: radiation and immune drug tested
NCT ID NCT02444741
Summary
This study is testing whether combining a targeted form of radiation therapy with an immunotherapy drug (pembrolizumab) is safe and more effective than the drug alone for patients with advanced non-small cell lung cancer that has spread. The goal is to see if the radiation helps the immune system better attack cancer cells throughout the body. The trial will enroll about 126 patients to find the best dose and measure how well the combination shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.